Literature DB >> 35583373

Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients.

Xuesong Han1, Jingxuan Zhao1, K Robin Yabroff1, Christopher J Johnson2, Ahmedin Jemal1.   

Abstract

BACKGROUND: Medicaid expansion under the Affordable Care Act (ACA) is associated with increased insurance coverage among patients with cancer. Whether these gains translate to improved survival is largely unknown. This study examines changes in 2-year survival among patients newly diagnosed with cancer following the ACA Medicaid expansion.
METHODS: Patients aged 18-62 years from 42 states' population-based cancer registries diagnosed pre (2010-2012) and post (2014-2016) ACA Medicaid expansion were followed through September 30, 2013, and December 31, 2017, respectively. Difference-in-differences (DD) analysis of 2-year overall survival was stratified by sex, race and ethnicity, census tract-level poverty, and rurality.
RESULTS: A total of 2 555 302 patients diagnosed with cancer were included from Medicaid expansion (n = 1 523 585) and nonexpansion (n = 1 031 717) states. The 2-year overall survival increased from 80.58% pre-ACA to 82.23% post-ACA in expansion states and from 78.71% to 80.04% in nonexpansion states, resulting in a net increase of 0.44 percentage points (ppt) (95% confidence interval [CI] = 0.24ppt to 0.64ppt) in expansion states after adjusting for sociodemographic factors. By cancer site, the net increase was greater for colorectal cancer (DD = 0.90ppt, 95% CI = 0.19ppt to 1.60ppt), lung cancer (DD = 1.29ppt, 95% CI = 0.50ppt to 2.08ppt), non-Hodgkin lymphoma (DD = 1.07ppt, 95% CI = 0.14ppt to 1.99ppt), pancreatic cancer (DD = 1.80ppt, 95% CI = 0.40ppt to 3.21ppt), and liver cancer (DD = 2.57ppt, 95% CI = 1.00ppt to 4.15ppt). The improvement in 2-year overall survival was larger among non-Hispanic Black patients (DD = 0.72ppt, 95% CI = 0.12ppt to 1.31ppt) and patients residing in rural areas (DD = 1.48ppt, 95% CI= -0.26ppt to 3.23ppt), leading to narrowing survival disparities by race and rurality.
CONCLUSIONS: Medicaid expansion was associated with greater increase in 2-year overall survival, and the increase was prominent among non-Hispanic Blacks and in rural areas, highlighting the role of Medicaid expansion in reducing health disparities. Future studies should monitor changes in longer-term health outcomes following the ACA.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2022        PMID: 35583373      PMCID: PMC9360456          DOI: 10.1093/jnci/djac077

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  29 in total

1.  Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes.

Authors:  David A Barrington; Jennifer A Sinnott; Corinne Calo; David E Cohn; Casey M Cosgrove; Ashley S Felix
Journal:  Gynecol Oncol       Date:  2020-06-09       Impact factor: 5.482

2.  Effect of Medicaid Expansions of 2014 on Overall and Early-Stage Cancer Diagnoses.

Authors:  Aparna Soni; Kosali Simon; John Cawley; Lindsay Sabik
Journal:  Am J Public Health       Date:  2017-12-21       Impact factor: 9.308

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Population-Level Disparities in COVID-19: Measuring the Independent Association of the Proportion of Black Population on COVID-19 Cases and Deaths in US Counties.

Authors:  Anne H Gaglioti; Chaohua Li; Megan D Douglas; Peter T Baltrus; Mitchell A Blount; Rabab Zahidi; Lee S Caplan; Robina Josiah Willock; Omofolarin B Fasuyi; Dominic H Mack
Journal:  J Public Health Manag Pract       Date:  2021 May-Jun 01

Review 5.  Understanding the Implications of Medicaid Expansion for Cancer Care in the US: A Review.

Authors:  Theresa Ermer; Samantha L Walters; Maureen E Canavan; Michelle C Salazar; Andrew X Li; Michael Doonan; Daniel J Boffa
Journal:  JAMA Oncol       Date:  2022-01-01       Impact factor: 31.777

6.  Evaluating Medicaid expansion benefits for patients with cancer: National Cancer Database analysis and systematic review.

Authors:  Neal H Nathan; Joshua Bakhsheshian; Li Ding; William J Mack; Frank J Attenello
Journal:  J Cancer Policy       Date:  2021-06-05

7.  Changes in Insurance Coverage and Stage at Diagnosis Among Nonelderly Patients With Cancer After the Affordable Care Act.

Authors:  Ahmedin Jemal; Chun Chieh Lin; Amy J Davidoff; Xuesong Han
Journal:  J Clin Oncol       Date:  2017-09-08       Impact factor: 44.544

Review 8.  Personalized Medicine: Recent Progress in Cancer Therapy.

Authors:  Valentina Gambardella; Noelia Tarazona; Juan Miguel Cejalvo; Pasquale Lombardi; Marisol Huerta; Susana Roselló; Tania Fleitas; Desamparados Roda; Andres Cervantes
Journal:  Cancers (Basel)       Date:  2020-04-19       Impact factor: 6.639

9.  COVID-19 mortality in California based on death certificates: disproportionate impacts across racial/ethnic groups and nativity.

Authors:  Erika Garcia; Sandrah P Eckel; Zhanghua Chen; Kenan Li; Frank D Gilliland
Journal:  Ann Epidemiol       Date:  2021-03-18       Impact factor: 3.797

10.  State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States.

Authors:  Stacey A Fedewa; Ella A Kazerooni; Jamie L Studts; Robert A Smith; Priti Bandi; Ann Goding Sauer; Megan Cotter; Helmneh M Sineshaw; Ahmedin Jemal; Gerard A Silvestri
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

View more
  1 in total

1.  Changes in Cancer Mortality by Race and Ethnicity Following the Implementation of the Affordable Care Act in California.

Authors:  Maria Elena Martinez; Scarlett L Gomez; Alison J Canchola; Debora L Oh; James D Murphy; Winta Mehtsun; K Robin Yabroff; Matthew P Banegas
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.